Clinical trials: Cerebral Disorder
Stroke, Hand Function
Development of a FES Device for Hand Use During Arm Activities Following Stroke
The goal of the study is to develop an individualized, synergy resistant, portable electromyographic (EMG)-driven functional electrical stimulation (FES) device that allows for Reliable and Intuitive control of hand (ReIn-Hand)…
- Trial name
- NCT03986216
- Testing
- ReIn-Hand device assisted home-based practice
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Intracranial Bleed, Falls
Falls Validation Study
Each year, one in three adults over the age of 65 has a fall. These falls lead to half a million Canadian emergency department patient visits annually and falls in older adults account for more than 3% of all emergency department…
- Trial name
- NCT07536906
- Testing
- Clinical Decision Rule
- Where
- 7 sites in United States, Canada
- Volunteers
- 4,000 people
- Sponsor
- Dr. Kerstin de Wit
Epilepsy
Multicenter Trial for Adults With Partial Seizures
To compare seizure frequency in patients with refactory partial seizures (with or without generalization) who are taking Talampanel versus placebo as an add-on therapy to other licensed concomitant antiepileptic drugs (AEDs) and…
- Trial name
- NCT00034814
- Testing
- Talampanel
- Volunteers
- 190 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Metabolism, Insulin Resistance
The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin
This study will investigate the non-growth-hormone-dependent metabolic effects of the hormone Ghrelin in growth hormone deficient subjects by examining the insulin tolerance as well as signal proteins in fat and muscle biopsies.
- Conditions
- Metabolism, Insulin Resistance, Hypopituitarism
- Trial name
- NCT01209416
- Testing
- Acipimox, Ghrelin
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- University of Aarhus
Clinical High Risk for Psychosis (CHR), Psychotic Disorders
Accelerated Neuromodulation Therapy and Neurocomputational Biomarkers in Individuals at Clinical High Risk for Psychosis
The goal of this study is to learn whether an accelerated form of neuromodulation therapy is safe, feasible, and well tolerated in young people at clinical high risk for psychosis (CHR-P), and whether it is associated with…
- Conditions
- Clinical High Risk for Psychosis (CHR), Psychotic Disorders, Prodromal Symptoms
- Trial name
- TMS-CHR (NCT07786714)
- Testing
- Active Intermittent Theta Burst Stimulation (BEAM-F3 Targeting)
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Douglas Mental Health University Institute
Preventing Stroke in Sickle Cell Anaemia
Preventing Stroke Triggers in Children With Sickle Cell Anaemia in Mulago Hospital, Kampala (PREST ): a Randomized Control Trial
Sickle cell anaemia (SCA) is a common hereditary haemoglobin disorder in Africa. World wide it is estimated that about 300,000 newborns are born every year. Of which 75% of them live in Sub-saharan Africa (SSA).
- Trial name
- PREST (NCT03666806)
- Testing
- Influenza vaccine
- Where
- Uganda
- Volunteers
- 150 people
- Sponsor
- Makerere University
Brain Tumors
Brain Areas of Time-To-Contact Perception: an Awake Surgery Study
During a brain surgery targeted to remove a brain tumor, the neurosurgeon wakes up the patient to delimit the tumor area exactly, and identify the surrounding areas, to limit the surgery damages.
- Trial name
- BRAIN-TIME (NCT04128306)
- Testing
- Behavioral task, Awake surgery, Neurological assessment
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Alzheimer's Disease
Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease
The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for Alzheimer's disease.
- Trial name
- NCT00555204
- Testing
- ABT-089
- Where
- 42 sites in United States
- Volunteers
- 337 people
- Sponsor
- Abbott
Cancer, Myocarditis
Randomized Controlled Study Evaluating the Efficacy of Hypnosis in Nuclear Medicine
In Nuclear Medicine, the examinations are long (20-60 minutes) and the patients must remain immobile, sometimes fasting. The anxiety of the latter can lead to poor quality examinations and sometimes, although already injected…
- Conditions
- Cancer, Myocarditis, Alzheimer Disease, Parkinson
- Trial name
- HYDEM (NCT06116084)
- Testing
- Ericksonian Hypnosis, Hypnosis
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Stroke, Traumatic Brain Injury
Targeting Osteosarcopaenia and Multimorbidity for Frailty Prevention
The aging population and its accompanying burden from non-communicable chronic diseases predicts an increasing impact imposed by frailty on healthcare systems.
- Conditions
- Stroke, Traumatic Brain Injury, Knee Osteoarthritis, Breast Cancer
- Trial name
- OPTIMA-C (NCT06073106)
- Where
- Singapore
- Volunteers
- 500 people
- Sponsor
- Tan Tock Seng Hospital
Major Depressive Disorder
Use of Multiple Brain Imaging Modalities (PET and MRS) to Identify Metabolic Abnormalities in Major Depression
Several lines of evidence support the existence of an underlying abnormality in brain energy metabolism may play a key role in the biology of mood disorders.
- Trial name
- NCT01465165
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Paul Carlson
Acute Ischemic Stroke
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
The purpose of this trial is to determine if intravenous administration of the metal ion trapping agent DP-b99 up to 9 hours following acute ischemic stroke onset, and then for 3 additional days (4 consecutive days in total) is…
- Trial name
- MACSI (NCT00893867)
- Testing
- DP-b99
- Where
- 154 sites in United States, Austria and 16 more
- Volunteers
- 446 people
- Sponsor
- D-Pharm Ltd.
Brain and Central Nervous System Tumors
Biological Therapy in Treating Patients With Primary or Advanced Glioma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells in patients with primary or…
- Trial name
- NCT00003067
- Testing
- aldesleukin, lymphokine-activated killer cells
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Stroke, Acute, Cerebral Infarction
Virtual Reality Glove for Hand and Arm Rehabilitation After Stroke
The Virtual Reality Glove for Hand and Arm Rehabilitation (vREHAB) trial is a randomized, controlled, phase 3 trial aiming to evaluate the safety, usability, and efficacy of a virtual reality biofeedback system (Neofect RAPAEL…
- Trial name
- vREHAB (NCT03741400)
- Testing
- Neofect RAPAEL Smart Glove
- Where
- 4 sites in United States, Belgium
- Volunteers
- 60 people
- Sponsor
- Stanford University
Cerebral Palsy
IMPACT of an Instrumented Measurement on a Performance Assessment in Cerebral Palsy Treatment
The goal of this study is to assess the impact of passive reflective markers on bimanual performance assessment scores in children with unilateral cerebral palsy.
- Trial name
- IMPACT² (NCT06565000)
- Testing
- AHA Not Instrumented then AHA Instrumented, AHA Instrumented then AHA Not Instrumented
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Centre Médico-Chirurgical de Réadaptation des Massues Croix Rouge Française
Healthy
Study of the Optimal Number of Repetitions to Investigate the Cerebral Activity by fNIRS During a Voluntary Movement and an Illusory Movement Induced by Vibration
The purpose of this study is to investigate the cerebral activation of healthy participants during a voluntary movement and an illusory movement induced by vibration.
- Trial name
- MoViBloc (NCT07203807)
- Testing
- Voluntary movement and illusory movement of the right upper limb induced by TVS.
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Stroke
EMG Controlled Device in Acute Rehabilitation After Acute Stroke
Stroke is a medically relevant problem for the aging population. Individuals with stroke experience a high amount of arm functional deficits despite receiving rehabilitation.
- Trial name
- NCT04599036
- Testing
- MARK
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Parkinson Disease
Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients
The objective of this trial is to evaluate non-inferiority of pramipexole Extended release to Immediate release at 18 weeks on the primary efficacy endpoint (Unified Parkinson's Disease Rating Scale II+III) in Chinese PD patients…
- Trial name
- NCT01191944
- Testing
- pramipexole immediate release tablet, pramipexole extended release tablet
- Where
- 20 sites in China
- Volunteers
- 475 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
Intravenous Thrombolysis and NOAC
New oral anticoagulants (NOACs), including rivaroxaban, apixaban, dabigatran, and edoxaban, have become the first-line therapy for preventing ischemic stroke associated with non-valvular atrial fibrillation (NVAF).
- Trial name
- NCT06749834
- Testing
- Intravenous thrombolysis
- Where
- 2 sites in China
- Volunteers
- 280 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Fabry Disease
Alternative Dosing and Regimen of Replagal to Treat Fabry Disease
The main goal of this study is to assess the pharmacodynamic effects of different or more frequent doses of Replagal compared to the standard dosing regimen.
- Trial name
- NCT00075244
- Testing
- Replagal
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.